… acute lymphoblastic leukemia (ALL), it can redirect and recruit unstimulated primary T cell in
… binding did not influence phenotype and function of DCs [8]. However, in contrast to in vitro …

… ) T cell therapy for the treatment of acute myeloid leukemia (AML) has the risk of toxicity to
normal myeloid cells. … After 8 days, we injected a single dose of non-transduced or CD7 CAR …

… Thymic stromal lymphopoietin (TSLP) is a biological agent similar to IL-7, which could play
an important role in hematopoietic cell maturation and pediatric acute lymphoblastic leukemia …

Background: Older adults with acute myeloid leukemia (AML) represent a vulnerable
population in whom disease-based and clinical risk factors, patient goals, prognosis, and …

In fit patients with newly diagnosed acute myeloid leukemia (AML), immediate treatment start
is recommended due to the poor prognosis of untreated acute leukemia. We explored the …

… (Ph)-negative acute lymphoblastic leukemia (ALL), combining … graft-versus-leukemia reaction
mediated by T cells of donor … UCBT, 8/8 matched URD bone marrow transplantation or 7/8 …

… Early T-cell precursor ALL (ETP-ALL) is an aggressive subtype of T-ALL that accounts for a
… Standard risk patients should receive a total of eight intrathecal chemotherapy doses while …

Background Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor
(CAR) T cells offer a novel form of CAR-T-cell product that is available for immediate clinical …

… by the Ten-Eleven-Translocation (TET) dioxygenase family [8]. TET family proteins are able
… of hematological malignancies, such as acute myeloid leukemia (AML), is closely associated …

… or lack of treatment response [8]. Cytogenetic and molecular … All three isoforms comprise
an N-terminal PH domain, a T-… activation mediated by PI3K requires translocation of Akt to the …